Target intelligence / Profile preview

Kunitz-type serine protease inhibitor (KPI)

Target
KPI
Molecular classification
Serine protease inhibitor, Kunitz-type domain-containing protein, Ion channel blocker
01

Overview

Kunitz-type serine protease inhibitor toxins are a prominent family of small, disulfide-rich proteins found extensively in the venoms of snakes, spiders, and other venomous organisms. These toxins are characterized by a conserved structural motif known as the Kunitz domain, which typically contains three highly stable disulfide bonds. Their primary biological mechanism involves the potent, competitive inhibition of host serine proteases, such as plasmin, trypsin, and kallikrein, which can lead to severe disruptions in blood coagulation and fibrinolysis (Ranasinghe & McManus, 2013). Additionally, some members of this family, such as dendrotoxins, have evolved to target voltage-gated potassium channels, acting as potent neurotoxins that trigger neurotransmitter release and convulsions (Wan et al., 2013). From a therapeutic perspective, these molecules have served as templates for drug development, most notably aprotinin, which was used clinically to reduce perioperative bleeding. However, their use as drugs or their presence in venom poses significant safety challenges, including the risk of life-threatening anaphylaxis and potential nephrotoxicity (UniProt KB). Modern research continues to explore these inhibitors as scaffolds for highly specific therapeutic agents targeting cancer and inflammatory pathways.

Other names
BPTI-like inhibitorKunitz-type venom proteinKunitz-type domainDendrotoxinTextilininSerine protease inhibitor Kunitz-type
02

Mechanism of action

Competitive inhibition of serine proteases via a non-cleavable bait loop that binds the active site; physical blockade of voltage-gated potassium channels.

03

Biological functions

Protease inhibitionIon channel modulationRegulation of blood coagulationFibrinolysis inhibition
04

Disease associations

EnvenomationHemorrhageInflammationCancerCoagulopathy
05

Safety considerations

AnaphylaxisRenal toxicityThrombotic riskImmunogenicity
06

Interacting drugs

Aprotinin

3 more in the full profile.

07

Biomarkers

Activated clotting time (ACT)Plasmin levelsKallikrein activityProthrombin time (PT)D-dimer

Beyond the preview

Go deeper on Kunitz-type serine protease inhibitor (KPI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kunitz-type serine protease inhibitor (KPI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call